As a consequence of a decrease in CYP2C9 activity, the clearance of the anticoagulant S-warfarin was reported to be substantially reduced in patients with end-stage renal disease [43, 48], and the warfarin dose requirements of patients with moderate and severe kidney impairment were significantly lower than those of no kidney disease [43]. This evidence concerns the gene CYP2C9 and chronic kidney disease.